9 results about "Hydantoin derivatives" patented technology

This invention discloses a eutectic solvent and its preparation, a metal leaching agent, and a metal leaching method. The eutectic solvent is prepared by mixing choline chloride and a sulfonamide compound in a specific ratio; the sulfonamide compound is sulfonamide, 4-amino-N-(aminoiminomethyl)benzenesulfonic acid, or p-aminobenzenesulfonamide. This invention provides a metal leaching agent containing the aforementioned eutectic solvent, which is a transparent liquid prepared from the eutectic solvent and an auxiliary agent. The auxiliary agent is at least one selected from 1,3-dibromo-5,5-dimethylhydantoin, 1,3-dichloro-5,5-dimethylhydantoin, N-chlorosuccinimide, N-bromosuccinimide, chloramine T, and sodium hypochlorite. The eutectic solvent of this invention is an environmentally friendly compound, and the metal leaching agent system containing this eutectic solvent possesses both good oxidizing and coordinating abilities, enabling the leaching of gold and palladium with rapid leaching speed and high extraction rate.

The present invention discloses a green and efficient method for preparing hydantoin molecular derivatives, comprising the following steps: S1, placing compound 1, compound 2, a solvent, and a base in a reaction flask for reaction according to the following reaction formula: #imgabs0#. The present invention develops a cascade nucleophilic / aza-Michael addition reaction of N-alkoxy β-oxo-acrylamide with isocyanate under Lewis base catalysis, obtaining various highly functionalized hydantoin derivatives with yields of 80-98% under mild reaction conditions. This method is characterized by low catalyst loading (1 mol%), high atom economy, simple operation, a wide substrate range, a short reaction time, and exhibits certain bactericidal activity.

The present invention relates to novel spirohydantoin derivatives having metalloprotease ADAMTS-4 inhibitory activity and uses thereof. The spirohydantoin derivatives described in the present invention are useful for the prevention or treatment of diseases caused by liver damage, such as fatty liver, liver cirrhosis, and the like.

The present invention relates to the synthesis of hydantoin derivatives, and in particular to the synthesis process of 3-(2,3-epoxypropyl)-5,5-dimethylhydantoin. Comprise the following steps: epichlorohydrin is ring-opened under the catalysis of a weak base and selectively undergoes a substitution reaction with the hydrogen on the nitrogen atom at position 3 of 5,5-dimethylhydantoin, and then a ring-closure reaction occurs under the catalysis of a strong base to generate 3-(2,3-epoxypropyl)-5,5-dimethylhydantoin, with a liquid chromatography purity of 99.4%. The present invention obtains an epoxy resin intermediate with a high nitrogen content, which can effectively improve the flame retardancy, heat resistance and electrochemical properties of epoxy resin, and is expected to promote the industrial application of epoxy resin in the fields of electronics, aerospace, etc.

The present invention discloses a flotation separation method for a copper-molybdenum mixed flotation concentrate. The method comprises the following steps: S1: After the copper-molybdenum mixed flotation concentrate is concentrated in a thickener, the overflow enters a water treatment system, and the underflow undergoes a roughing operation, a cleaning operation, and a scavenging operation to obtain a first-stage copper concentrate and a copper-molybdenum concentrate; S2: After the copper-molybdenum concentrate is concentrated, the underflow is fed into a mill for agitator grinding; S3: The stirred milled product in S2 undergoes three cleaning operations and two scavenging operations to obtain a final molybdenum concentrate and a second-stage copper concentrate. The copper-molybdenum separation inhibitor is prepared from tetramethylthiouracil, thiohydantoin, chloroacetate, tributyl phosphonate, and polyethylene glycol. The newly prepared chalcopyrite inhibitor used in the present invention can completely replace sodium sulfide, achieving a molybdenum recovery rate of over 80% and a copper recovery rate of over 99%, thereby achieving efficient separation of the copper-molybdenum mixed flotation concentrate.

An immediate-release liquid oral suspension of Eslicarbazepine Acetate, containing between about 5 to about 10 g of active ingredient per 100 mL, along with carbomer homopolymer and microcrystalline cellulose as viscosity modifying agents. It may further comprise, parabens as antimicrobial agent, sucralose as a sweetener, and polyethylene glycol 8 stearate as a surfactant. The suspension is designed to provide bioequivalence to marketed Eslicarbazepine Acetate tablets, ensuring rapid drug release and stability over extended storage periods. The pH is adjusted to 3.0-6.5 to maintain stability, with impurities remaining under 0.05% of the eslicarbazepine content after stress storage conditions. This formulation offers an alternative to solid dosage forms for patients with partial-onset seizures.

To provide a method for efficiently producing a halogeno-2,4-substituted benzoic acid derivative and to provide methods for producing a benzophenone derivative and a halogenobenzene derivative using the halogeno-2,4-substituted benzoic acid derivative produced by the method.SOLUTION: A method for producing a halogeno-2,4-substituted benzoic acid derivative represented by formula (VI), the method including bringing a 2,4-substituted benzoic acid derivative represented by formula (V) into contact with a halogenating agent, the halogenating agent containing at least one compound selected from the group consisting of N-bromosuccinimide, 1,3-dibromo-5,5-dimethylhydantoin, N-chlorosuccinimide, and 1,3-dichloro-5,5-dimethylhydantoin.SELECTED DRAWING: None

The invention discloses a method for synthesizing a compound containing a hydantoin skeleton with optical activity, comprising the steps of: directly adding L-homoproline, a derivative of acetophenone hydrazone, and copper acetylacetonate to an organic solvent, acetonitrile, heating an oil bath to 90-120°C under a nitrogen atmosphere, reacting for 12-24 hours, and post-processing to obtain the optically pure hydantoin derivative. The method utilizes simple, easy-to-prepare, stable acetophenone hydrazone derivatives and L-homoproline as reaction substrates, and in the absence of an oxidant, a strong acid, and a strong base, smoothly realizes the one-step preparation of an optically pure hydantoin skeleton via a tandem cyclization reaction process under a copper catalysis system. The conversion has excellent atom economy and step economy, a wide substrate range, and good functional group compatibility, and provides a new and efficient synthesis method for the preparation of optically pure derivatives containing a hydantoin skeleton with biological activity.

The present application relates to a kind of thiohydantoin drug intermediates and its preparation method and purposes, specifically disclosed the compound of formula (I) and various preparation methods thereof, and first adopt the compound of formula (I) and the compound of formula (V) are prepared by ring closing reaction, such as the thiohydantoin drug shown in formula (VI).